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The goal of precision medicine is to use population based molecular, clinical 
and other data to make individually-tailored clinical decisions for patients, 
though the path to achieving this goal is not entirely clear. A new study shows 
how knowledge banks of patient data can be used to make individual 
treatment decisions in acute myeloid leukemia.  
 
Our understanding of the molecular diversity of disease is increasing dramatically, and 
unveiling vast complexity. The longstanding premise that diseases that appear 
morphologically similar or even identical are underpinned by similar molecular and genetic 
abnormalities has proven to be incorrect. As a consequence, developing therapies that target 
specific molecular processes for these diseases is becoming more and more challenging as 
ever increasing sub-groups of diminishing size are replacing what was previously a single 
disease entity.  This perhaps explains why many potential therapies have failed particularly in 
cancer, and why many current therapies are only effective in sub-groups that cannot be 
predicted prior to treatment.  Given these challenges, how do we approach the treatment of 
disease with what is now variably termed precision, personalised, individualised, or stratified 
medicine? On page XXX of this issue, Peter Campbell, Hartmut Döhner and colleagues 
present one potential approach for making individualized clinical care decisions in the 
treatment of acute myeloid leukemia (AML) patients1. The approach leverages information 
from a large number of AML patients in order to predict the best treatment for an individual 
patient.   
 
The knowledge bank approach 
At first observation, this approach may appear obvious: accumulate a knowledge base—often 
referred to as a knowledge bank—that captures the clinical features and the molecular 
pathology of diseases of many patients, ideally within a health system environment to guide 
optimal treatment choices. The end goal of such a strategy is to enable what is referred to as 
a self-learning health system, where accrued data informs ongoing development of 
interventions and processes. Based on this concept, many large-scale efforts have been 
initiated including the 100,000 Genomes Project in the UK2, the Precision Medicine Initiative 
in the United States3 and the Global Alliance for Genomics and Health4, as well as many others 
across the globe.   
 
The central belief is that having these data together will allow us to make better informed 
choices with regard to individual patients.  However, the mechanism as to how we make these 
treatment decisions in a robust way, the metrics, parameters and statistics that will be required 
are yet to be established.  The article by Gerstung et al.1 is perhaps the first description of how 
a knowledge bank approach can, and potentially should be used to inform clinical decisions. 
In this case, the article explores the knowledge bank idea in the context of AML.   Treatment 
  
of this disease has advanced dramatically over the last several decades, and central to the 
treatment is the requirement for a bone marrow transplant. Whilst effective, bone marrow 
transplantation is not without significant morbidity and potential mortality, and has a substantial 
cost implication.  
 
The authors show that by compiling the genetic, clinical and molecular attributes for individual 
patients they can cluster them into sub-groups where more informed decisions can be made 
about an individual’s treatment choice (Figure 1). Perhaps the most challenging question 
concerning transplantation in AML is whether or not to transplant at first remission after 
induction chemotherapy. Patients who are in remission can either receive consolidation 
chemotherapy or a bone marrow transplant. There are currently no means to determine which 
path is optimal for each patient. Using the knowledge bank as presented by Gertsung et al., 
20-25% of patients have the option of chemotherapy rather than transplantation with the same 
overall long-term outcome. This is an important decision as transplantation is associated with 
a 20% mortality risk and increased morbidity. 
 
Moving knowledge to the clinic 
Whilst knowledge banks containing large numbers will be important, the numbers required to 
address current key clinical questions are not staggeringly large.  The study by Gertsung et 
al. reports on 1,540 patients, with the dramatic findings that almost a quarter of patients can 
have their therapy decision changed based on this knowledge bank approach. Of course, as 
we delve into smaller and smaller clinically relevant subgroups, the numbers will need to 
increase. However, the ability to dramatically inform treatment decisions as the authors 
demonstrate, with considerable benefits in morbidity and mortality, and substantial potential 
cost savings epitomize the goals of precision oncology. 
 
Some may reasonably argue that we have always used a knowledge bank approach in clinical 
medicine. That knowledge bank resides within the experienced clinician who takes information 
from various sources, most of which imperfectly reflects the clinical scenario of the patient in 
front of them, and synthesise the information to make a treatment decision.  This “clinical 
judgement” is based on an individual’s experience and knowledge base, which the “knowledge 
banks” of the future aim to enhance. 
  
As demonstrated by Gertsung et al. we can refine current therapeutic choices for available 
therapies using a knowledge bank approach. This then raises the question as to whether the 
data reported here are ready to be used in the clinic as part of routine practice. In the current 
environment, the answer is no, and a randomised, appropriately controlled study is feasible to 
address this question and further validate the selection model prior to implementation. Yet if 
the ultimate goal is to use knowledge banks to improve healthcare, and we are faced with ever 
increasing diversity and complexity of disease, data emerging from larger knowledge banks 
may not be tractable to test using traditional clinical trial designs. Defining quality standards, 
particularly for clinical data and metrics around what is considered to be an effective 
intervention, and the path to broader implementation and regulatory approval will be vital if we 
are to effectively realise the promise of knowledge banks for clinical medicine.  
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Figure 1. The knowledge bank approach. A knowledge Bank accrues information from 
parameters that are relevant to the disease and its treatment permitting novel generalizable 
insights about the disease and its subgroups. An individual patient’s specific characteristics 
are reflected upon the knowledge bank to define an individual’s risk profile for different 
treatment choices. As the number of participants in the knowledge bank grows, the confidence 
with which predictions for individual patients continuously grows. The sediment plots show the 
risk of each outcome over time for each treatment choice. 
